Asleh K, et al. - Experts evaluated the capacity of basal biomarkers nestin and inositol-polyphosphate-4-phosphate (INPP4B) to identify which patients benefit from gemcitabine in metastatic breast cancer. They used the interaction tests, Kaplan-Meier curves and forest plots to evaluate the prognostic and predictive capacities of biomarkers relative to treatment. Significantly better overall survival on gemcitabine-docetaxel vs docetaxel monotherapy was seen in the patients assigned as immunohistochemistry (IHC) basal “nestin+ or INPP4B-” within an estimated median follow-up of 13 years, whereas no differences were observed for other patients.